{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:34Z","timestamp":1792783234464,"version":"4.5.0"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH","award":["T32EB006359"],"award-info":[{"award-number":["T32EB006359"]}]},{"name":"NIH","award":["5R01DE030350"],"award-info":[{"award-number":["5R01DE030350"]}]},{"name":"NIH","award":["5R01CA296810"],"award-info":[{"award-number":["5R01CA296810"]}]},{"name":"NIH","award":["5R01EB038005"],"award-info":[{"award-number":["5R01EB038005"]}]},{"name":"NIH","award":["5R01GM117150"],"award-info":[{"award-number":["5R01GM117150"]}]},{"name":"NIH","award":["5R01CA274743"],"award-info":[{"award-number":["5R01CA274743"]}]},{"name":"NIH","award":["5R01CA201446"],"award-info":[{"award-number":["5R01CA201446"]}]},{"name":"NIH","award":["1UL1TR001430"],"award-info":[{"award-number":["1UL1TR001430"]}]},{"name":"PhRMA Foundation","award":["0000 0000 9959 8153"],"award-info":[{"award-number":["0000 0000 9959 8153"]}],"id":[{"id":"https:\/\/ror.org\/029sjzg14","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["2421692"],"award-info":[{"award-number":["2421692"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-23-1-0819"],"award-info":[{"award-number":["HT9425-23-1-0819"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11095-026-04174-5","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:35:27Z","timestamp":1788212127000},"page":"2529-2551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic Medicine Approaches for Tumor Suppressor Loss: Therapeutic Replacement with Self-Amplifying RNA"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6271-4293","authenticated-orcid":false,"given":"Devin","family":"Mutha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaithanya P.","family":"Vedula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Bhagavatula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Grinstaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Ganem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"4174_CR1","unstructured":"Joyce C, Rayi A, Kasi A. Tumor-suppressor genes. [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532243\/"},{"key":"4174_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.celrep.2018.12.066","volume":"26","author":"P Jia","year":"2019","unstructured":"Jia P, Zhao Z. Characterization of tumor-suppressor gene inactivation events in 33 cancer types. Cell Rep. 2019;26:496-506.e3. https:\/\/doi.org\/10.1016\/j.celrep.2018.12.066.","journal-title":"Cell Rep"},{"key":"4174_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.582","volume":"5","author":"TC Dakal","year":"2024","unstructured":"Dakal TC, Dhabhai B, Pant A, et al. Oncogenes and tumor suppressor genes: functions and roles in cancers. MedComm. 2024;5: e582. https:\/\/doi.org\/10.1002\/mco2.582.","journal-title":"MedComm"},{"key":"4174_CR4","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1038\/s41388-021-01852-z","volume":"40","author":"T Barnoud","year":"2021","unstructured":"Barnoud T, Indeglia A, Murphy ME. Shifting the paradigms for tumor suppression: lessons from the p53 field. Oncogene. 2021;40:4281\u201390. https:\/\/doi.org\/10.1038\/s41388-021-01852-z.","journal-title":"Oncogene"},{"key":"4174_CR5","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1159\/000495956","volume":"51","author":"L-H Wang","year":"2018","unstructured":"Wang L-H, Wu C-F, Rajasekaran N, et al. Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview. Cell Physiol Biochem. 2018;51:2647\u201393. https:\/\/doi.org\/10.1159\/000495956.","journal-title":"Cell Physiol Biochem"},{"key":"4174_CR6","unstructured":"cBioPortal for Cancer Genomics: AMER1, BIRC3 and 11 other genes in MSK-IMPACT 50K Clinical Sequencing Cohort (MSK, Cancer Cell 2026) n.d.  https:\/\/www.cbioportal.org\/results\/cancerTypesSummary?cancer_study_list=msk_impact_50k_2026&Z_SCORE_THRESHOLD=2.0&RPPA_SCORE_THRESHOLD=2.0&profileFilter=mutations%2Cstructural_variants%2Cgistic&case_set_id=msk_impact_50k_2026_cnaseq&gene_list=AMER1%250ABIRC3%250ACDKN2A%250ALATS2%250AMAP2K4%250ANF1%250APTEN%250ARB1%250ASMAD4%250ASMARCB1%2520%250ASTK11%250ATP53%250AVHL&geneset_list=%20&tab_index=tab_visualize&Action=Submit. Accessed 30 Apr 2026."},{"key":"4174_CR7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1134\/S0006297918110019","volume":"83","author":"Y Jiao","year":"2018","unstructured":"Jiao Y, Feng Y, Wang X. Regulation of tumor suppressor gene CDKN2A and encoded p16-INK4a protein by covalent modifications. Biochem Mosc. 2018;83:1289\u201398. https:\/\/doi.org\/10.1134\/S0006297918110019.","journal-title":"Biochem Mosc"},{"key":"4174_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081076","volume":"11","author":"F Luongo","year":"2019","unstructured":"Luongo F, Colonna F, Calap\u00e0 F, et al. PTEN tumor-suppressor: the dam of stemness in cancer. Cancers. 2019;11: 1076. https:\/\/doi.org\/10.3390\/cancers11081076.","journal-title":"Cancers"},{"key":"4174_CR9","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.1128\/MCB.00105-19","volume":"39","author":"AE Marshall","year":"2019","unstructured":"Marshall AE, Roes MV, Passos DT, et al. RB1 Deletion in Retinoblastoma Protein Pathway-Disrupted Cells Results in DNA Damage and Cancer Progression. Mol Cell Biol. 2019;39:e00105-e119. https:\/\/doi.org\/10.1128\/MCB.00105-19.","journal-title":"Mol Cell Biol"},{"key":"4174_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12401","volume":"26","author":"W Ren","year":"2017","unstructured":"Ren W, Gu G. Prognostic implications of RB1 tumour suppressor gene alterations in the clinical outcome of human osteosarcoma: a meta-analysis. Eur J Cancer Care (Engl). 2017;26: e12401. https:\/\/doi.org\/10.1111\/ecc.12401.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"4174_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.33197","volume":"148","author":"MJ Duffy","year":"2021","unstructured":"Duffy MJ, Crown J. Drugging, \u201cundruggable\u201d genes for cancer treatment: are we making progress? Int J Cancer. 2021;148:8\u201317. https:\/\/doi.org\/10.1002\/ijc.33197.","journal-title":"Int J Cancer"},{"key":"4174_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41368-021-00145-1","volume":"13","author":"Y Li","year":"2021","unstructured":"Li Y, Guo W, Li X, et al. Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers. Int J Oral Sci. 2021;13:38. https:\/\/doi.org\/10.1038\/s41368-021-00145-1.","journal-title":"Int J Oral Sci"},{"key":"4174_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/v16071094","volume":"16","author":"M Salauddin","year":"2024","unstructured":"Salauddin M, Saha S, Hossain MdG, et al. Clinical application of adenovirus (AdV): a comprehensive review. Viruses. 2024;16: 1094. https:\/\/doi.org\/10.3390\/v16071094.","journal-title":"Viruses"},{"key":"4174_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6:53. https:\/\/doi.org\/10.1038\/s41392-021-00487-6.","journal-title":"Signal Transduct Target Ther"},{"key":"4174_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Gessler DJ, Zhan W, et al. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9:78. https:\/\/doi.org\/10.1038\/s41392-024-01780-w.","journal-title":"Signal Transduct Target Ther"},{"key":"4174_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","volume":"11","author":"D Xiao","year":"2026","unstructured":"Xiao D, Zhang H, Liu Y, et al. Oncolytic viruses: advanced strategies in cancer therapy. Signal Transduct Target Ther. 2026;11:45. https:\/\/doi.org\/10.1038\/s41392-025-02343-3.","journal-title":"Signal Transduct Target Ther"},{"key":"4174_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17010104","volume":"17","author":"MA Lu\u00eds","year":"2025","unstructured":"Lu\u00eds MA, Goes MAD, Santos FM, et al. Plasmid gene therapy for monogenic disorders: challenges and perspectives. Pharmaceutics. 2025;17: 104. https:\/\/doi.org\/10.3390\/pharmaceutics17010104.","journal-title":"Pharmaceutics"},{"key":"4174_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14091861","volume":"14","author":"DH Mart\u00ednez-Puente","year":"2022","unstructured":"Mart\u00ednez-Puente DH, P\u00e9rez-Trujillo JJ, Zavala-Flores LM, et al. Plasmid DNA for therapeutic applications in cancer. Pharmaceutics. 2022;14: 1861. https:\/\/doi.org\/10.3390\/pharmaceutics14091861.","journal-title":"Pharmaceutics"},{"key":"4174_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102721","author":"MA Ige","year":"2025","unstructured":"Ige MA, Ren X, Yang Y, et al. mRNA therapeutics: transforming medicine through innovation in design, delivery, and disease treatment. Mol Ther Nucleic Acids. 2025. https:\/\/doi.org\/10.1016\/j.omtn.2025.102721.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4174_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12020102","volume":"12","author":"A Wadhwa","year":"2020","unstructured":"Wadhwa A, Aljabbari A, Lokras A, et al. Opportunities and challenges in the delivery of mRNA-Based vaccines. Pharmaceutics. 2020;12: 102. https:\/\/doi.org\/10.3390\/pharmaceutics12020102.","journal-title":"Pharmaceutics"},{"key":"4174_CR21","doi-asserted-by":"publisher","first-page":"6439","DOI":"10.1128\/JVI.67.11.6439-6446.1993","volume":"67","author":"PJ Bredenbeek","year":"1993","unstructured":"Bredenbeek PJ, Frolov I, Rice CM, et al. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol. 1993;67:6439\u201346. https:\/\/doi.org\/10.1128\/JVI.67.11.6439-6446.1993.","journal-title":"J Virol"},{"key":"4174_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1006\/viro.1997.8878","volume":"239","author":"P Pushko","year":"1997","unstructured":"Pushko P, Parker M, Ludwig GV, et al. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genesin vitro and immunization against heterologous pathogensin vivo. Virology. 1997;239:389\u2013401. https:\/\/doi.org\/10.1006\/viro.1997.8878.","journal-title":"Virology"},{"key":"4174_CR23","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.1209367109","volume":"109","author":"AJ Geall","year":"2012","unstructured":"Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci. 2012;109:14604\u20139. https:\/\/doi.org\/10.1073\/pnas.1209367109.","journal-title":"Proc Natl Acad Sci"},{"key":"4174_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","volume":"26","author":"AK Blakney","year":"2019","unstructured":"Blakney AK, McKay PF, Yus BI, et al. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther. 2019;26:363\u201372. https:\/\/doi.org\/10.1038\/s41434-019-0095-2.","journal-title":"Gene Ther"},{"key":"4174_CR25","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","volume":"11","author":"PF McKay","year":"2020","unstructured":"McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun. 2020;11:3523. https:\/\/doi.org\/10.1038\/s41467-020-17409-9.","journal-title":"Nat Commun"},{"key":"4174_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","volume":"24","author":"Y Oda","year":"2024","unstructured":"Oda Y, Kumagai Y, Kanai M, et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect Dis. 2024;24:351\u201360. https:\/\/doi.org\/10.1016\/S1473-3099(23)00650-3.","journal-title":"Lancet Infect Dis"},{"key":"4174_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29225315","volume":"29","author":"Y Peng","year":"2024","unstructured":"Peng Y, Bai J, Li W, et al. Advancements in p53-based anti-tumor gene therapy research. Molecules. 2024;29: 5315. https:\/\/doi.org\/10.3390\/molecules29225315.","journal-title":"Molecules"},{"key":"4174_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/biom13010159","volume":"13","author":"B Wallis","year":"2023","unstructured":"Wallis B, Bowman KR, Lu P, et al. The challenges and prospects of p53-based therapies in ovarian cancer. Biomolecules. 2023;13: 159. https:\/\/doi.org\/10.3390\/biom13010159.","journal-title":"Biomolecules"},{"key":"4174_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102313","author":"Z Eftekhari","year":"2024","unstructured":"Eftekhari Z, Zohrabi H, Oghalaie A, et al. Advancements and challenges in mRNA and ribonucleoprotein-based therapies: from delivery systems to clinical applications. Mol Ther Nucleic Acids. 2024. https:\/\/doi.org\/10.1016\/j.omtn.2024.102313.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4174_CR30","doi-asserted-by":"publisher","unstructured":"Savostyanova TA, Lopatnikova JA, Sennikov SV. The guardian of the genome meets immunotherapy: p53-based strategies. Front Immunol. n.d.;17:1762679. https:\/\/doi.org\/10.3389\/fimmu.2026.1762679.","DOI":"10.3389\/fimmu.2026.1762679"},{"key":"4174_CR31","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc A, Querbes W, De S, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18:1357\u201364. https:\/\/doi.org\/10.1038\/mt.2010.85.","journal-title":"Mol Ther"},{"key":"4174_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.omtn.2021.11.018","volume":"27","author":"J Ai","year":"2022","unstructured":"Ai J, Li J, Su Q, et al. rAAV-delivered PTEN therapeutics for prostate cancer. Mol Ther Nucleic Acids. 2022;27:122\u201332. https:\/\/doi.org\/10.1016\/j.omtn.2021.11.018.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4174_CR33","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ultrasmedbio.2020.11.001","volume":"47","author":"C Li","year":"2021","unstructured":"Li C, Hu S, Yue Y. Ultrasound microbubble-mediated VHL regulates the biological behavior of ovarian cancer cells. Ultrasound Med Biol. 2021;47:723\u201332. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2020.11.001.","journal-title":"Ultrasound Med Biol"},{"key":"4174_CR34","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41587-024-02306-z","volume":"43","author":"JE McGee","year":"2025","unstructured":"McGee JE, Kirsch JR, Kenney D, et al. Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency. Nat Biotechnol. 2025;43:720\u20136. https:\/\/doi.org\/10.1038\/s41587-024-02306-z.","journal-title":"Nat Biotechnol"},{"key":"4174_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2022.07.016","volume":"143","author":"IZM Kreuger","year":"2023","unstructured":"Kreuger IZM, Slieker RC, van Groningen T, et al. Therapeutic strategies for targeting CDKN2A loss in melanoma. J Invest Dermatol. 2023;143:18-25.e1. https:\/\/doi.org\/10.1016\/j.jid.2022.07.016.","journal-title":"J Invest Dermatol"},{"key":"4174_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.addr.2015.12.005","volume":"98","author":"KL Nastiuk","year":"2016","unstructured":"Nastiuk KL, Krolewski JJ. Opportunities and challenges in combination gene cancer therapy. Adv Drug Deliv Rev. 2016;98:35\u201340. https:\/\/doi.org\/10.1016\/j.addr.2015.12.005.","journal-title":"Adv Drug Deliv Rev"},{"key":"4174_CR37","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","volume":"33","author":"IC Casmil","year":"2025","unstructured":"Casmil IC, Jin J, Won E-J, et al. The advent of clinical self-amplifying RNA vaccines. Mol Ther. 2025;33:2565\u201382. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.060.","journal-title":"Mol Ther"},{"key":"4174_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18010144","volume":"18","author":"A-C Wu","year":"2025","unstructured":"Wu A-C, Nakamura Y, Kiyotani K. Advances in neoantigen-based cancer vaccines. Cancers. 2025;18:144. https:\/\/doi.org\/10.3390\/cancers18010144.","journal-title":"Cancers"},{"key":"4174_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"key":"4174_CR40","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature. 2025;639:1042\u201351. https:\/\/doi.org\/10.1038\/s41586-024-08508-4.","journal-title":"Nature"},{"key":"4174_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00262-025-03992-7","volume":"74","author":"CM Nguyen","year":"2025","unstructured":"Nguyen CM, Vu TT, Nguyen MN, et al. Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model. Cancer Immunol Immunother. 2025;74:145. https:\/\/doi.org\/10.1007\/s00262-025-03992-7.","journal-title":"Cancer Immunol Immunother"},{"key":"4174_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","volume":"112","author":"T Ishida","year":"2006","unstructured":"Ishida T, Ichihara M, Wang X, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release. 2006;112:15\u201325. https:\/\/doi.org\/10.1016\/j.jconrel.2006.01.005.","journal-title":"J Control Release"},{"key":"4174_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154\u2013155","author":"GT Kozma","year":"2020","unstructured":"Kozma GT, Shimizu T, Ishida T, et al. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154\u2013155:163\u201375. https:\/\/doi.org\/10.1016\/j.addr.2020.07.024.","journal-title":"Adv Drug Deliv Rev"},{"key":"4174_CR44","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","volume":"9","author":"RP Garay","year":"2012","unstructured":"Garay RP, El-Gewely R, Armstrong JK, et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9:1319\u201323. https:\/\/doi.org\/10.1517\/17425247.2012.720969.","journal-title":"Expert Opin Drug Deliv"},{"key":"4174_CR45","doi-asserted-by":"publisher","unstructured":"Yousefpour P, Gregory JR, Si K, et al. Engineering drug-responsive replication machinery for precise control of self-amplifying RNA. Nat Biomed Eng. 2026;1\u201317. https:\/\/doi.org\/10.1038\/s41551-026-01723-6.","DOI":"10.1038\/s41551-026-01723-6"},{"key":"4174_CR46","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.molpharmaceut.2c00010","volume":"19","author":"C Webb","year":"2022","unstructured":"Webb C, Ip S, Bathula NV, et al. Current status and future perspectives on mRNA drug manufacturing. Mol Pharm. 2022;19:1047\u201358. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00010.","journal-title":"Mol Pharm"},{"key":"4174_CR47","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1021\/acs.molpharmaceut.2c00032","volume":"19","author":"HH Ly","year":"2022","unstructured":"Ly HH, Daniel S, Soriano SKV, et al. Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of-Experiment Approach. Mol Pharm. 2022;19:1892\u2013905. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00032.","journal-title":"Mol Pharm"},{"key":"4174_CR48","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","volume":"18","author":"Z Sondka","year":"2018","unstructured":"Sondka Z, Bamford S, Cole CG, et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18:696\u2013705. https:\/\/doi.org\/10.1038\/s41568-018-0060-1.","journal-title":"Nat Rev Cancer"},{"key":"4174_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, et al. Targeting p53 pathways: mechanisms, structures and advances in therapy. Signal Transduct Target Ther. 2023;8:92. https:\/\/doi.org\/10.1038\/s41392-023-01347-1.","journal-title":"Signal Transduct Target Ther"},{"key":"4174_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05408-1","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang T, Su W, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13: 974. https:\/\/doi.org\/10.1038\/s41419-022-05408-1.","journal-title":"Cell Death Dis"},{"key":"4174_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188556","volume":"1876","author":"LJ Hern\u00e1ndez Borrero","year":"2021","unstructured":"Hern\u00e1ndez Borrero LJ, El-Deiry WS. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021;1876: 188556. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188556.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"4174_CR52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature17157","volume":"531","author":"Y Liu","year":"2016","unstructured":"Liu Y, Chen C, Xu Z, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature. 2016;531:471\u20135. https:\/\/doi.org\/10.1038\/nature17157.","journal-title":"Nature"},{"key":"4174_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107720","volume":"220","author":"J Huang","year":"2021","unstructured":"Huang J. Current developments of targeting the p53 signaling pathway for cancer treatment. Pharmacol Ther. 2021;220:107720. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107720.","journal-title":"Pharmacol Ther"},{"key":"4174_CR54","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/hum.2017.218","volume":"29","author":"W-W Zhang","year":"2018","unstructured":"Zhang W-W, Li L, Li D, et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther. 2018;29:160\u201379. https:\/\/doi.org\/10.1089\/hum.2017.218.","journal-title":"Hum Gene Ther"},{"key":"4174_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645745","volume":"11","author":"RE Sobol","year":"2021","unstructured":"Sobol RE, Menander KB, Chada S, et al. Analysis of adenoviral p53 gene therapy clinical trials in recurrent head and neck squamous cell carcinoma. Front Oncol. 2021;11: 645745. https:\/\/doi.org\/10.3389\/fonc.2021.645745.","journal-title":"Front Oncol"},{"key":"4174_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.101155","volume":"11","author":"L Qi","year":"2023","unstructured":"Qi L, Li G, Li P, et al. Twenty years of Gendicine\u00ae rAd-p53 cancer gene therapy: the first-in-class human cancer gene therapy in the era of personalized oncology. Genes Dis. 2023;11: 101155. https:\/\/doi.org\/10.1016\/j.gendis.2023.101155.","journal-title":"Genes Dis"},{"key":"4174_CR57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/dddt.s3535","volume":"2","author":"G Ma","year":"2009","unstructured":"Ma G, Shimada H, Hiroshima K, et al. Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China. Drug Des Devel Ther. 2009;2:115\u201322. https:\/\/doi.org\/10.2147\/dddt.s3535.","journal-title":"Drug Des Devel Ther"},{"key":"4174_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","volume":"66","author":"M Goldstein","year":"2015","unstructured":"Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med. 2015;66:129\u201343. https:\/\/doi.org\/10.1146\/annurev-med-081313-121208.","journal-title":"Annu Rev Med"},{"key":"4174_CR59","unstructured":"Introgen Therapeutics. Effectiveness and safety of INGN 201 in combination with chemotherapy versus chemotherapy alone. NCT00041626. clinicaltrials.gov; 2007. https:\/\/clinicaltrials.gov\/study\/NCT00041626."},{"key":"4174_CR60","unstructured":"Introgen Therapeutics. Study to compare the overall survival of patients receiving INGN 201 (Study Drug) with patients receiving methotrexate. NCT00041613. clinicaltrials.gov; 2008. https:\/\/clinicaltrials.gov\/study\/NCT00041613."},{"key":"4174_CR61","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2147\/OTT.S50483","volume":"7","author":"G Chen","year":"2014","unstructured":"Chen G, Zhang S, He X, et al. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. OncoTargets Ther. 2014;7:1901\u20139. https:\/\/doi.org\/10.2147\/OTT.S50483.","journal-title":"OncoTargets Ther"},{"key":"4174_CR62","unstructured":"Merck Sharp & Dohme LLC. A Phase I Study in Patients With Peritoneal Carcinomatosis Using SCH 58500 (rAd\/p53) Administered by Single Intraperitoneal Instillation. clinicaltrials.gov; 2016."},{"key":"4174_CR63","unstructured":"National Cancer Institute (NCI). Assessment of the safety and transduction efficiency of SCH58500, an adenoviral vector p53 delivery system, to patients with recurrent malignant brain tumors. NCT00004080. clinicaltrials.gov; 2009. https:\/\/clinicaltrials.gov\/study\/NCT00004080."},{"key":"4174_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1484982","volume":"7","author":"S-S Kim","year":"2018","unstructured":"Kim S-S, Harford JB, Moghe M, et al. Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor. Oncoimmunology. 2018;7: e1484982. https:\/\/doi.org\/10.1080\/2162402X.2018.1484982.","journal-title":"Oncoimmunology"},{"key":"4174_CR65","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/mt.2013.32","volume":"21","author":"N Senzer","year":"2013","unstructured":"Senzer N, Nemunaitis J, Nemunaitis D, et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther. 2013;21:1096\u2013103. https:\/\/doi.org\/10.1038\/mt.2013.32.","journal-title":"Mol Ther"},{"key":"4174_CR66","unstructured":"SynerGene Therapeutics, Inc. A phase I open-label safety and pharmacokinetic study of escalating doses of SGT-53 for infusion in subjects with advanced solid tumors. NCT00470613. clinicaltrials.gov; 2017. https:\/\/clinicaltrials.gov\/study\/NCT00470613."},{"key":"4174_CR67","unstructured":"SynerGene Therapeutics, Inc. Phase II study of combined targeted p53 gene therapy (SGT-53) plus gemcitabine\/nab-paclitaxel for treatment of metastatic pancreatic cancer. NCT02340117. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT02340117."},{"key":"4174_CR68","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1200\/JCO.2021.39.15_suppl.4139","volume":"39","author":"CP Leung","year":"2021","unstructured":"Leung CP, Barve MA, Wu M-S, et al. A phase II trial combining tumor-targeting TP53 gene therapy with gemcitabine\/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer. J Clin Oncol. 2021;39:4139\u20134139. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4139.","journal-title":"J Clin Oncol"},{"key":"4174_CR69","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/mt.2016.135","volume":"24","author":"KF Pirollo","year":"2016","unstructured":"Pirollo KF, Nemunaitis J, Leung PK, et al. Safety and efficacy in advanced solid tumors of a targeted nanocomplex carrying the p53 gene used in combination with docetaxel: a phase 1b study. Mol Ther. 2016;24:1697\u2013706. https:\/\/doi.org\/10.1038\/mt.2016.135.","journal-title":"Mol Ther"},{"key":"4174_CR70","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41417-021-00369-7","volume":"29","author":"S Chada","year":"2022","unstructured":"Chada S, Wiederhold D, Menander KB, et al. Tumor suppressor immune gene therapy to reverse immunotherapy resistance. Cancer Gene Ther. 2022;29:825\u201334. https:\/\/doi.org\/10.1038\/s41417-021-00369-7.","journal-title":"Cancer Gene Ther"},{"key":"4174_CR71","unstructured":"MultiVir, Inc. A Phase 2, Multi-Center, Open Label Study to Evaluate Adenoviral p53 (Ad-p53) in Combination With Immune Checkpoint Inhibitor Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Tumors Approved for Anti-PD-1 or Anti-PD-L1 Therapy. clinicaltrials.gov; 2020."},{"key":"4174_CR72","unstructured":"Northwestern University. A pilot study of SGT-53 with carboplatin and pembrolizumab in metastatic triple negative inflammatory breast cancer. NCT05093387. clinicaltrials.gov; 2022. https:\/\/clinicaltrials.gov\/study\/NCT05093387."},{"key":"4174_CR73","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1565","volume":"11","author":"N Kong","year":"2019","unstructured":"Kong N, Tao W, Ling X, et al. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Sci Transl Med. 2019;11: eaaw1565. https:\/\/doi.org\/10.1126\/scitranslmed.aaw1565.","journal-title":"Sci Transl Med"},{"key":"4174_CR74","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41467-022-28279-8","volume":"13","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Chen J, Zhou H, et al. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat Commun. 2022;13:758. https:\/\/doi.org\/10.1038\/s41467-022-28279-8.","journal-title":"Nat Commun"},{"key":"4174_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1409519","volume":"14","author":"L Du","year":"2024","unstructured":"Du L, Zhang Q, Li Y, et al. Research progress on the role of PTEN deletion or mutation in the immune microenvironment of glioblastoma. Front Oncol. 2024;14: 1409519. https:\/\/doi.org\/10.3389\/fonc.2024.1409519.","journal-title":"Front Oncol"},{"key":"4174_CR76","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15:222\u201334. https:\/\/doi.org\/10.1038\/nrurol.2018.9.","journal-title":"Nat Rev Urol"},{"key":"4174_CR77","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41419-025-08022-z","volume":"16","author":"M Vidal-Saban\u00e9s","year":"2025","unstructured":"Vidal-Saban\u00e9s M, Bonifaci N, Navaridas R, et al. Endometrial cancer progression driven by PTEN-deficiency requires miR-424(322)~503. Cell Death Dis. 2025;16:705. https:\/\/doi.org\/10.1038\/s41419-025-08022-z.","journal-title":"Cell Death Dis"},{"key":"4174_CR78","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.70054","volume":"38","author":"GL Parkman","year":"2025","unstructured":"Parkman GL, Xu X, Holmen SL, et al. The roles of PTEN in melanoma suppression. Pigment Cell Melanoma Res. 2025;38:e70054. https:\/\/doi.org\/10.1111\/pcmr.70054.","journal-title":"Pigment Cell Melanoma Res"},{"key":"4174_CR79","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","volume":"10","author":"C Costa","year":"2020","unstructured":"Costa C, Wang Y, Ly A, et al. PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer. Cancer Discov. 2020;10:72\u201385. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0830.","journal-title":"Cancer Discov"},{"key":"4174_CR80","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/sj.gt.3302100","volume":"10","author":"Y Saito","year":"2003","unstructured":"Saito Y, Swanson X, Mhashilkar AM, et al. Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Ther. 2003;10:1961\u20139. https:\/\/doi.org\/10.1038\/sj.gt.3302100.","journal-title":"Gene Ther"},{"key":"4174_CR81","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00384-013-1678-9","volume":"28","author":"Z Li","year":"2013","unstructured":"Li Z, Liu GX, Liu YL, et al. Effect of adenovirus-mediated PTEN gene on ulcerative colitis-associated colorectal cancer. Int J Colorectal Dis. 2013;28:1107\u201315. https:\/\/doi.org\/10.1007\/s00384-013-1678-9.","journal-title":"Int J Colorectal Dis"},{"key":"4174_CR82","unstructured":"Minaguchi T, Mori T, Kanamori Y, et al. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the pten gene. Cancer Res. 1999 Dec 15;59(24):6063\u20137."},{"key":"4174_CR83","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/cgt.2015.59","volume":"23","author":"H Zhang","year":"2016","unstructured":"Zhang H, Zhou X, Xu C, et al. Synergistic tumor suppression by adenovirus-mediated ING4\/PTEN double gene therapy for gastric cancer. Cancer Gene Ther. 2016;23:13\u201323. https:\/\/doi.org\/10.1038\/cgt.2015.59.","journal-title":"Cancer Gene Ther"},{"key":"4174_CR84","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3748\/wjg.v11.i15.2224","volume":"11","author":"Y Hang","year":"2005","unstructured":"Hang Y, Zheng Y-C, Cao Y, et al. Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene. World J Gastroenterol. 2005;11:2224\u20139. https:\/\/doi.org\/10.3748\/wjg.v11.i15.2224.","journal-title":"World J Gastroenterol"},{"key":"4174_CR85","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/sj.cgt.7701050","volume":"14","author":"G Pappas","year":"2007","unstructured":"Pappas G, Zumstein LA, Munshi A, et al. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther. 2007;14:543\u20139. https:\/\/doi.org\/10.1038\/sj.cgt.7701050.","journal-title":"Cancer Gene Ther"},{"key":"4174_CR86","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3892\/ijo.15.6.1069","volume":"15","author":"A Sakurada","year":"1999","unstructured":"Sakurada A, Hamada H, Fukushige S, et al. Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer. Int J Oncol. 1999;15:1069\u2013143. https:\/\/doi.org\/10.3892\/ijo.15.6.1069.","journal-title":"Int J Oncol"},{"key":"4174_CR87","first-page":"1904","volume":"8","author":"MA Davies","year":"2002","unstructured":"Davies MA, Kim SJ, Parikh NU, et al. Adenoviral-mediated expression of MMAC\/PTEN inhibits proliferation and metastasis of human prostate cancer cells1. Clin Cancer Res. 2002;8:1904\u201314.","journal-title":"Clin Cancer Res"},{"key":"4174_CR88","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1000-1948(10)60039-1","volume":"25","author":"L Yuhuan","year":"2010","unstructured":"Yuhuan L, Jiaqi W, Peili Y, et al. Adenovirus-mediated PTEN gene transfection suppresses growth and promotes chemosensitivity of endometrial carcinoma. J Med Coll PLA. 2010;25:193\u2013203. https:\/\/doi.org\/10.1016\/S1000-1948(10)60039-1.","journal-title":"J Med Coll PLA"},{"key":"4174_CR89","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/sj.gt.3302056","volume":"10","author":"M Tanaka","year":"2003","unstructured":"Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther. 2003;10:1636\u201342. https:\/\/doi.org\/10.1038\/sj.gt.3302056.","journal-title":"Gene Ther"},{"key":"4174_CR90","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.cdp.2004.07.006","volume":"29","author":"M Tanaka","year":"2005","unstructured":"Tanaka M, Rosser CJ, Grossman HB. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detect Prev. 2005;29:170\u20134. https:\/\/doi.org\/10.1016\/j.cdp.2004.07.006.","journal-title":"Cancer Detect Prev"},{"key":"4174_CR91","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.apsb.2023.06.006","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Yang L, Ou Y, et al. Combination of AAV-delivered tumor suppressor PTEN with anti-PD-1 loaded depot gel for enhanced antitumor immunity. Acta Pharm Sin B. 2024;14:350\u201364. https:\/\/doi.org\/10.1016\/j.apsb.2023.06.006.","journal-title":"Acta Pharm Sin B"},{"key":"4174_CR92","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1038\/s41467-018-07344-1","volume":"9","author":"L Russell","year":"2018","unstructured":"Russell L, Swanner J, Jaime-Ramirez AC, et al. PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance. Nat Commun. 2018;9:5006. https:\/\/doi.org\/10.1038\/s41467-018-07344-1.","journal-title":"Nat Commun"},{"key":"4174_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035153","volume":"7","author":"M Ding","year":"2012","unstructured":"Ding M, Cao X, Xu H, et al. Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene. PLoS ONE. 2012;7: e35153. https:\/\/doi.org\/10.1371\/journal.pone.0035153.","journal-title":"PLoS ONE"},{"key":"4174_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2024.14752","volume":"29","author":"S Kim","year":"2025","unstructured":"Kim S, Jung B-K, Kim J, et al. Anticancer effect of the oncolytic Newcastle disease virus harboring the PTEN gene on glioblastoma. Oncol Lett. 2025;29:1\u201313. https:\/\/doi.org\/10.3892\/ol.2024.14752.","journal-title":"Oncol Lett"},{"key":"4174_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200898","author":"S Kim","year":"2024","unstructured":"Kim S, Jung B-K, Kim J, et al. Newcastle disease virus harboring the PTEN gene inhibits pancreatic cancer growth by inhibiting PI3K\/AKT\/mTOR signaling and activating apoptosis. Mol Ther Oncolytics. 2024. https:\/\/doi.org\/10.1016\/j.omton.2024.200898.","journal-title":"Mol Ther Oncolytics"},{"key":"4174_CR96","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.omto.2023.03.003","volume":"29","author":"U Sahu","year":"2023","unstructured":"Sahu U, Mullarkey MP, Pei G, et al. OHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy. Mol Ther Oncolytics. 2023;29:30\u201341. https:\/\/doi.org\/10.1016\/j.omto.2023.03.003.","journal-title":"Mol Ther Oncolytics"},{"key":"4174_CR97","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.omtn.2022.12.016","volume":"31","author":"GL Gregory","year":"2023","unstructured":"Gregory GL, Copple IM. Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer. Mol Ther Nucleic Acids. 2023;31:211\u201323. https:\/\/doi.org\/10.1016\/j.omtn.2022.12.016.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4174_CR98","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41551-018-0284-0","volume":"2","author":"MA Islam","year":"2018","unstructured":"Islam MA, Xu Y, Tao W, et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018;2:850\u201364. https:\/\/doi.org\/10.1038\/s41551-018-0284-0.","journal-title":"Nat Biomed Eng"},{"key":"4174_CR99","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba9772","volume":"13","author":"Y-X Lin","year":"2021","unstructured":"Lin Y-X, Wang Y, Ding J, et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci Transl Med. 2021;13: eaba9772. https:\/\/doi.org\/10.1126\/scitranslmed.aba9772.","journal-title":"Sci Transl Med"},{"key":"4174_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124519","volume":"662","author":"J Sam Lee","year":"2024","unstructured":"Sam Lee J, Kim M, Jin H, et al. DNA aptamer-conjugated lipid nanoparticle for targeted PTEN mRNA delivery to prostate cancer cells. Int J Pharm. 2024;662: 124519. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124519.","journal-title":"Int J Pharm"},{"key":"4174_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309917","volume":"11","author":"Y Kim","year":"2024","unstructured":"Kim Y, Choi J, Kim EH, et al. Design of PD-L1-targeted lipid nanoparticles to turn on PTEN for efficient cancer therapy. Adv Sci. 2024;11: 2309917. https:\/\/doi.org\/10.1002\/advs.202309917.","journal-title":"Adv Sci"},{"key":"4174_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2026.201133","volume":"34","author":"B Hu","year":"2026","unstructured":"Hu B, Wu P, Zheng L, et al. Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption. Mol Ther Oncol. 2026;34: 201133. https:\/\/doi.org\/10.1016\/j.omton.2026.201133.","journal-title":"Mol Ther Oncol"},{"key":"4174_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2026.201194","volume":"34","author":"Y Otsuka","year":"2026","unstructured":"Otsuka Y, Watanabe T, Kudo M. A novel cancer gene therapy achieving reciprocal regulation of PTEN and PARP1 expression. Mol Ther Oncol. 2026;34:201194. https:\/\/doi.org\/10.1016\/j.omton.2026.201194.","journal-title":"Mol Ther Oncol"},{"key":"4174_CR104","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2015","unstructured":"Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15:55\u201364. https:\/\/doi.org\/10.1038\/nrc3844.","journal-title":"Nat Rev Cancer"},{"key":"4174_CR105","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41392-023-01362-2","volume":"8","author":"J Hu","year":"2023","unstructured":"Hu J, Tan P, Ishihara M, et al. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. Signal Transduct Target Ther. 2023;8:155. https:\/\/doi.org\/10.1038\/s41392-023-01362-2.","journal-title":"Signal Transduct Target Ther"},{"key":"4174_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-15192-8","volume":"25","author":"K Rhein","year":"2025","unstructured":"Rhein K, Kotsis F, Ganner A, et al. Belzutifan for patients with Von Hippel-Lindau (VHL) disease-associated heterogeneous tumors \u2013 a retrospective single center analysis. BMC Cancer. 2025;25: 1686. https:\/\/doi.org\/10.1186\/s12885-025-15192-8.","journal-title":"BMC Cancer"},{"key":"4174_CR107","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1479-5876-9-46","volume":"9","author":"Z Xu","year":"2011","unstructured":"Xu Z, Shen G, Xia X, et al. Comparisons of three polyethyleneimine-derived nanoparticles as a gene therapy delivery system for renal cell carcinoma. J Transl Med. 2011;9:46. https:\/\/doi.org\/10.1186\/1479-5876-9-46.","journal-title":"J Transl Med"},{"key":"4174_CR108","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41417-018-0041-2","volume":"26","author":"C Chen","year":"2019","unstructured":"Chen C, Tian A, Zhao M, et al. Adenoviral delivery of VHL suppresses bone sarcoma cell growth through inhibition of Wnt\/\u03b2-catenin signaling. Cancer Gene Ther. 2019;26:83\u201393. https:\/\/doi.org\/10.1038\/s41417-018-0041-2.","journal-title":"Cancer Gene Ther"},{"key":"4174_CR109","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s42003-020-0873-9","volume":"3","author":"ES Knudsen","year":"2020","unstructured":"Knudsen ES, Nambiar R, Rosario SR, et al. Pan-cancer molecular analysis of the RB tumor suppressor pathway. Commun Biol. 2020;3:158. https:\/\/doi.org\/10.1038\/s42003-020-0873-9.","journal-title":"Commun Biol"},{"key":"4174_CR110","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-22-1115","volume":"28","author":"CA Febres-Aldana","year":"2022","unstructured":"Febres-Aldana CA, Chang JC, Ptashkin R, et al. Rb tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct Rb-proficient subset. Clin Cancer Res. 2022;28:4702\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1115.","journal-title":"Clin Cancer Res"},{"key":"4174_CR111","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41389-023-00475-1","volume":"12","author":"M Shrestha","year":"2023","unstructured":"Shrestha M, Wang D-Y, Ben-David Y, et al. CDK4\/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer. Oncogenesis. 2023;12:29. https:\/\/doi.org\/10.1038\/s41389-023-00475-1.","journal-title":"Oncogenesis"},{"key":"4174_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081558","volume":"16","author":"M-F Huang","year":"2024","unstructured":"Huang M-F, Wang Y-X, Chou Y-T, et al. Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy. Cancers. 2024;16:1558. https:\/\/doi.org\/10.3390\/cancers16081558.","journal-title":"Cancers"},{"key":"4174_CR113","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/nm1296-1316","volume":"2","author":"DJ Riley","year":"1996","unstructured":"Riley DJ, Nikitin AY, Lee W-H. Adenovirus\u2013mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+\/\u2212 mice. Nat Med. 1996;2:1316\u201321. https:\/\/doi.org\/10.1038\/nm1296-1316.","journal-title":"Nat Med"},{"key":"4174_CR114","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/iovs.64.15.31","volume":"64","author":"H Shi","year":"2023","unstructured":"Shi H, He X, Yang Z, et al. The use of rAAV2-RB1\u2013mediated gene therapy in retinoblastoma. Invest Ophthalmol Vis Sci. 2023;64:31. https:\/\/doi.org\/10.1167\/iovs.64.15.31.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4174_CR115","doi-asserted-by":"publisher","first-page":"9624","DOI":"10.1073\/pnas.97.17.9624","volume":"97","author":"I Schwarte-Waldhoff","year":"2000","unstructured":"Schwarte-Waldhoff I, Volpert OV, Bouck NP, et al. Smad4\/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A. 2000;97:9624\u20139. https:\/\/doi.org\/10.1073\/pnas.97.17.9624.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4174_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189220","volume":"1879","author":"H Yao","year":"2024","unstructured":"Yao H, Luo L, Li R, et al. New insight into the role of SMAD4 mutation\/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas. Biochim Biophys Acta Rev Cancer. 2024;1879: 189220. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189220.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"4174_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01864-9","volume":"21","author":"T Fang","year":"2021","unstructured":"Fang T, Liang T, Wang Y, et al. Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21: 297. https:\/\/doi.org\/10.1186\/s12876-021-01864-9.","journal-title":"BMC Gastroenterol"},{"key":"4174_CR118","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41416-025-03002-8","volume":"132","author":"M Sun","year":"2025","unstructured":"Sun M, Gu Y, Wang J, et al. Smad4 loss identifies aggressive subtype with immunotherapy and anti-HER-2 treatment resistance in gastric cancer. Br J Cancer. 2025;132:1148\u201357. https:\/\/doi.org\/10.1038\/s41416-025-03002-8.","journal-title":"Br J Cancer"},{"key":"4174_CR119","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021873","volume":"8","author":"M Morikawa","year":"2016","unstructured":"Morikawa M, Derynck R, Miyazono K. TGF-\u03b2 and the TGF-\u03b2 family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8: a021873. https:\/\/doi.org\/10.1101\/cshperspect.a021873.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4174_CR120","first-page":"3628","volume":"8","author":"B Peng","year":"2002","unstructured":"Peng B, Fleming JB, Breslin T, et al. Suppression of tumorigenesis and induction of p15ink4b by Smad4\/DPC4 in human pancreatic cancer cells1. Clin Cancer Res. 2002;8:3628\u201338.","journal-title":"Clin Cancer Res"},{"key":"4174_CR121","first-page":"5656","volume":"58","author":"KK Hunt","year":"1998","unstructured":"Hunt KK, Fleming JB, Abramian A, et al. Overexpression of the tumor suppressor gene Smad4\/DPC4 induces p21waf1 expression and growth inhibition in human carcinoma cells1. Cancer Res. 1998;58:5656\u201361.","journal-title":"Cancer Res"},{"key":"4174_CR122","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.intimp.2015.01.022","volume":"25","author":"Z Yang","year":"2015","unstructured":"Yang Z, Zhong L, Zhong S, et al. Adenovirus encoding Smad4 suppresses glioma cell proliferation and increases apoptosis through cell cycle arrest at G1 phase. Int Immunopharmacol. 2015;25:169\u201373. https:\/\/doi.org\/10.1016\/j.intimp.2015.01.022.","journal-title":"Int Immunopharmacol"},{"key":"4174_CR123","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.1038\/sj.onc.1206751","volume":"22","author":"DG Duda","year":"2003","unstructured":"Duda DG, Sunamura M, Lefter LP, et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene. 2003;22:6857\u201364. https:\/\/doi.org\/10.1038\/sj.onc.1206751.","journal-title":"Oncogene"},{"key":"4174_CR124","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41417-025-00976-8","volume":"32","author":"C Dai","year":"2025","unstructured":"Dai C, Zhao Y, Zhang H, et al. SMAD4-armed oncolytic adenovirus therapy potentiates the chemotherapy effects in NSCLC through suppression of the Wnt\/\u03b2-catenin pathway. Cancer Gene Ther. 2025;32:1439\u201352. https:\/\/doi.org\/10.1038\/s41417-025-00976-8.","journal-title":"Cancer Gene Ther"},{"key":"4174_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8120593","volume":"8","author":"B Xiao","year":"2020","unstructured":"Xiao B, Zhang L, Liu H, et al. Oncolytic adenovirus CD55-Smad4 suppresses cell proliferation, metastasis, and tumor stemness in colorectal cancer by regulating Wnt\/\u03b2-catenin signaling pathway. Biomedicines. 2020;8: 593. https:\/\/doi.org\/10.3390\/biomedicines8120593.","journal-title":"Biomedicines"},{"key":"4174_CR126","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/s41467-023-37020-y","volume":"14","author":"M Hu","year":"2023","unstructured":"Hu M, Feng C, Yuan Q, et al. Lantern-shaped flexible RNA origami for Smad4 mRNA delivery and growth suppression of colorectal cancer. Nat Commun. 2023;14:1307. https:\/\/doi.org\/10.1038\/s41467-023-37020-y.","journal-title":"Nat Commun"},{"key":"4174_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153645","volume":"14","author":"GW Cooper","year":"2022","unstructured":"Cooper GW, Hong AL. SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities. Cancers. 2022;14: 3645. https:\/\/doi.org\/10.3390\/cancers14153645.","journal-title":"Cancers"},{"key":"4174_CR128","doi-asserted-by":"publisher","first-page":"7762","DOI":"10.1038\/s41467-023-43498-3","volume":"14","author":"NQ Liu","year":"2023","unstructured":"Liu NQ, Paassen I, Custers L, et al. SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors. Nat Commun. 2023;14:7762. https:\/\/doi.org\/10.1038\/s41467-023-43498-3.","journal-title":"Nat Commun"},{"key":"4174_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115727","volume":"215","author":"C Lanzi","year":"2023","unstructured":"Lanzi C, Arrighetti N, Pasquali S, et al. Targeting EZH2 in SMARCB1-deficient sarcomas: advances and opportunities to potentiate the efficacy of EZH2 inhibitors. Biochem Pharmacol. 2023;215: 115727. https:\/\/doi.org\/10.1016\/j.bcp.2023.115727.","journal-title":"Biochem Pharmacol"},{"key":"4174_CR130","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.2147\/IJN.S458323","volume":"19","author":"S-S Kim","year":"2024","unstructured":"Kim S-S, Moghe M, Rait A, et al. SMARCB1 gene therapy using a novel tumor-targeted nanomedicine enhances anti-cancer efficacy in a mouse model of atypical teratoid rhabdoid tumors. Int J Nanomedicine. 2024;19:5973\u201393. https:\/\/doi.org\/10.2147\/IJN.S458323.","journal-title":"Int J Nanomedicine"},{"key":"4174_CR131","doi-asserted-by":"publisher","unstructured":"Rossi M, Pellegrini C, Cardelli L, et al. Familial melanoma: diagnostic and management implications. Dermatol Pract Concept. 2019:10\u20136. https:\/\/doi.org\/10.5826\/dpc.0901a03.","DOI":"10.5826\/dpc.0901a03"},{"key":"4174_CR132","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1097\/MPA.0000000000001888","volume":"50","author":"H Kimura","year":"2021","unstructured":"Kimura H, Klein AP, Hruban RH, et al. The role of inherited pathogenic CDKN2A variants in susceptibility to pancreatic cancer. Pancreas. 2021;50:1123. https:\/\/doi.org\/10.1097\/MPA.0000000000001888.","journal-title":"Pancreas"},{"key":"4174_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156177","volume":"274","author":"X Feng","year":"2025","unstructured":"Feng X, Chang H, Xu Y, et al. CDKN2A alternations in non-small cell lung cancer: an evaluation using next-generation sequencing. Pathol Res Pract. 2025;274: 156177. https:\/\/doi.org\/10.1016\/j.prp.2025.156177.","journal-title":"Pathol Res Pract"},{"key":"4174_CR134","first-page":"961","volume":"2","author":"AWC Lee","year":"2003","unstructured":"Lee AWC, Li J-H, Shi W, et al. P16 gene therapy: a potentially efficacious modality for nasopharyngeal carcinoma. Mol Cancer Ther. 2003;2:961\u20139.","journal-title":"Mol Cancer Ther"},{"key":"4174_CR135","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s003450050182","volume":"18","author":"JA Allay","year":"2000","unstructured":"Allay JA, Steiner MS, Zhang Y, et al. Adenovirus p16 gene therapy for prostate cancer. World J Urol. 2000;18:111\u201320. https:\/\/doi.org\/10.1007\/s003450050182.","journal-title":"World J Urol"},{"key":"4174_CR136","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1006\/bbrc.2001.5565","volume":"287","author":"T-J Wang","year":"2001","unstructured":"Wang T-J, Huang M-S, Hong C-Y, et al. Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ. Biochem Biophys Res Commun. 2001;287:173\u201380. https:\/\/doi.org\/10.1006\/bbrc.2001.5565.","journal-title":"Biochem Biophys Res Commun"},{"key":"4174_CR137","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/ijc.20065","volume":"110","author":"AA Li","year":"2004","unstructured":"Li AA, Ng E, Shi W, et al. Potential efficacy of p16 gene therapy for EBV-positive nasopharyngeal carcinoma. Int J Cancer. 2004;110:452\u20138. https:\/\/doi.org\/10.1002\/ijc.20065.","journal-title":"Int J Cancer"},{"key":"4174_CR138","first-page":"1697","volume":"4","author":"JW Rocco","year":"1998","unstructured":"Rocco JW, Li D, Liggett WH Jr, et al. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res. 1998;4:1697\u2013704.","journal-title":"Clin Cancer Res"},{"key":"4174_CR139","doi-asserted-by":"publisher","unstructured":"Rhee JG, Li D, O\u2019Malley BW Jr, et al. Combination radiation and adenovirus-mediated p16INK4A gene therapy in a murine model for head and neck cancer. ORL. 2003;65:144\u201354. https:\/\/doi.org\/10.1159\/000072252.","DOI":"10.1159\/000072252"},{"key":"4174_CR140","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/sj.cgt.7700226","volume":"7","author":"I Campbell","year":"2000","unstructured":"Campbell I, Magliocco A, Moyana T, et al. Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth. Cancer Gene Ther. 2000;7:1270\u20138. https:\/\/doi.org\/10.1038\/sj.cgt.7700226.","journal-title":"Cancer Gene Ther"},{"key":"4174_CR141","first-page":"4275","volume":"18","author":"I Naruse","year":"1998","unstructured":"Naruse I, Heike Y, Hama S, et al. High concentrations of recombinant adenovirus expressing p16 gene induces apoptosis in lung cancer cell lines. Anticancer Res. 1998;18:4275\u201382.","journal-title":"Anticancer Res"},{"key":"4174_CR142","first-page":"4182","volume":"5","author":"S Kobayashi","year":"1999","unstructured":"Kobayashi S, Shirasawa H, Sashiyama H, et al. P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5:4182\u20135.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"4174_CR143","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/sj.gt.3302238","volume":"11","author":"IA McNeish","year":"2004","unstructured":"McNeish IA, Bell SJ, Lemoine NR. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther. 2004;11:497\u2013503. https:\/\/doi.org\/10.1038\/sj.gt.3302238.","journal-title":"Gene Ther"},{"key":"4174_CR144","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1038\/sj.onc.1205458","volume":"21","author":"PG Hemmati","year":"2002","unstructured":"Hemmati PG, Gillissen B, von Haefen C, et al. Adenovirus-mediated overexpression of p14ARF induces p53 and Bax-independent apoptosis. Oncogene. 2002;21:3149\u201361. https:\/\/doi.org\/10.1038\/sj.onc.1205458.","journal-title":"Oncogene"},{"key":"4174_CR145","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/sj.cgt.7700505","volume":"9","author":"N Saadatmandi","year":"2002","unstructured":"Saadatmandi N, Tyler T, Huang Y, et al. Growth suppression by a p14ARF exon 1\u03b2 adenovirus in human tumor cell lines of varying p53 and Rb status. Cancer Gene Ther. 2002;9:830\u20139. https:\/\/doi.org\/10.1038\/sj.cgt.7700505.","journal-title":"Cancer Gene Ther"},{"key":"4174_CR146","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1089\/104303402760128595","volume":"13","author":"Y Tango","year":"2002","unstructured":"Tango Y, Fujiwara T, Itoshima T, et al. Adenovirus-Mediated p14ARF Gene Transfer Cooperates with Ad5CMV-p53 to Induce Apoptosis in Human Cancer Cells. Hum Gene Ther. 2002;13:1373\u201382. https:\/\/doi.org\/10.1089\/104303402760128595.","journal-title":"Hum Gene Ther"},{"key":"4174_CR147","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0006-291X(02)00948-8","volume":"296","author":"X Deng","year":"2002","unstructured":"Deng X, Kim M, Vandier D, et al. Recombinant adenovirus-mediated p14ARF overexpression sensitizes human breast cancer cells to cisplatin. Biochem Biophys Res Commun. 2002;296:792\u20138. https:\/\/doi.org\/10.1016\/S0006-291X(02)00948-8.","journal-title":"Biochem Biophys Res Commun"},{"key":"4174_CR148","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/sj.onc.1206303","volume":"22","author":"B Eymin","year":"2003","unstructured":"Eymin B, Leduc C, Coll J-L, et al. p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene. 2003;22:1822\u201335. https:\/\/doi.org\/10.1038\/sj.onc.1206303.","journal-title":"Oncogene"},{"key":"4174_CR149","doi-asserted-by":"publisher","unstructured":"Yang C-T, You L, Yeh C-C, et al. Adenovirus-mediated p14ARF gene transfer in human mesothelioma cells. J Natl Cancer Inst . 2000 Apr 19;92(8):636-41.\u00a0\u00a0https:\/\/doi.org\/10.1093\/jnci\/92.8.636.","DOI":"10.1093\/jnci\/92.8.636"},{"key":"4174_CR150","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/cdd.2017.99","volume":"24","author":"N Furth","year":"2017","unstructured":"Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 2017;24:1488\u2013501. https:\/\/doi.org\/10.1038\/cdd.2017.99.","journal-title":"Cell Death Differ"},{"key":"4174_CR151","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1101\/gad.1909210","volume":"24","author":"B Zhao","year":"2010","unstructured":"Zhao B, Li L, Lei Q, et al. The Hippo\u2013YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24:862\u201374. https:\/\/doi.org\/10.1101\/gad.1909210.","journal-title":"Genes Dev"},{"key":"4174_CR152","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41388-025-03387-z","volume":"44","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Abedini A, Rodriguez GM, et al. Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression. Oncogene. 2025;44:2240\u201352. https:\/\/doi.org\/10.1038\/s41388-025-03387-z.","journal-title":"Oncogene"},{"key":"4174_CR153","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.3892\/ol.2017.7535","volume":"15","author":"S Matsui","year":"2018","unstructured":"Matsui S, Kagara N, Mishima C, et al. LATS2 promoter hypermethylation and its effect on gene expression in human breast cancer. Oncol Lett. 2018;15:2595\u2013603. https:\/\/doi.org\/10.3892\/ol.2017.7535.","journal-title":"Oncol Lett"},{"key":"4174_CR154","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","volume":"5","author":"EA Chapeau","year":"2024","unstructured":"Chapeau EA, Sansregret L, Galli GG, et al. Direct and selective pharmacological disruption of the YAP\u2013TEAD interface by IAG933 inhibits Hippo-dependent and RAS\u2013MAPK-altered cancers. Nat Cancer. 2024;5:1102\u201320. https:\/\/doi.org\/10.1038\/s43018-024-00754-9.","journal-title":"Nat Cancer"},{"key":"4174_CR155","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.stem.2020.03.002","volume":"26","author":"Q Li","year":"2020","unstructured":"Li Q, Sun Y, Jarugumilli GK, et al. Lats1\/2 sustain intestinal stem cells through TEAD-dependent and independent transcription. Cell Stem Cell. 2020;26:675-692.e8. https:\/\/doi.org\/10.1016\/j.stem.2020.03.002.","journal-title":"Cell Stem Cell"},{"key":"4174_CR156","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70338","volume":"6","author":"R Bala","year":"2025","unstructured":"Bala R, Madaan R, Bedi O, et al. Targeting the Hippo\/YAP pathway: a promising approach for cancer therapy and beyond. MedComm. 2025;6: e70338. https:\/\/doi.org\/10.1002\/mco2.70338.","journal-title":"MedComm"},{"key":"4174_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102715","volume":"10","author":"ER Barry","year":"2021","unstructured":"Barry ER, Simov V, Valtingojer I, et al. Recent therapeutic approaches to modulate the Hippo pathway in oncology and regenerative medicine. Cells. 2021;10: 2715. https:\/\/doi.org\/10.3390\/cells10102715.","journal-title":"Cells"},{"key":"4174_CR158","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1101\/gad.1447006","volume":"20","author":"Y Aylon","year":"2006","unstructured":"Aylon Y, Michael D, Shmueli A, et al. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev. 2006;20:2687\u2013700. https:\/\/doi.org\/10.1101\/gad.1447006.","journal-title":"Genes Dev"},{"key":"4174_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113110","author":"S Lei","year":"2023","unstructured":"Lei S, Chen C, Han F, et al. AMER1 deficiency promotes the distant metastasis of colorectal cancer by inhibiting SLC7A11- and FTL-mediated ferroptosis. Cell Rep. 2023. https:\/\/doi.org\/10.1016\/j.celrep.2023.113110.","journal-title":"Cell Rep"},{"key":"4174_CR160","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31798","volume":"72","author":"I Campwala","year":"2025","unstructured":"Campwala I, Schienda J, Murphy AJ, et al. Wilms tumor in children with AMER1\/WTX germline pathogenic variants: a multicenter case series. Pediatr Blood Cancer. 2025;72: e31798. https:\/\/doi.org\/10.1002\/pbc.31798.","journal-title":"Pediatr Blood Cancer"},{"key":"4174_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113110","volume":"42","author":"S Lei","year":"2023","unstructured":"Lei S, Chen C, Han F, et al. AMER1 deficiency promotes the distant metastasis of colorectal cancer by inhibiting SLC7A11- and FTL-mediated ferroptosis. Cell Rep. 2023;42: 113110. https:\/\/doi.org\/10.1016\/j.celrep.2023.113110.","journal-title":"Cell Rep."},{"key":"4174_CR162","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s43556-025-00327-x","volume":"6","author":"J Liang","year":"2025","unstructured":"Liang J, Pan Y, Yang J, et al. WNT signaling in cancer: molecular mechanisms and potential therapies. Mol Biomed. 2025;6:83. https:\/\/doi.org\/10.1186\/s43556-025-00327-x.","journal-title":"Mol Biomed"},{"key":"4174_CR163","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.852185","volume":"10","author":"T-M Theilen","year":"2022","unstructured":"Theilen T-M, Braun Y, Bochennek K, et al. Multidisciplinary treatment strategies for Wilms tumor: recent advances, technical innovations and future directions. Front Pediatr. 2022;10: 852185. https:\/\/doi.org\/10.3389\/fped.2022.852185.","journal-title":"Front Pediatr"},{"key":"4174_CR164","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1126\/science\/1141515","volume":"316","author":"MB Major","year":"2007","unstructured":"Major MB, Camp ND, Berndt JD, et al. Wilms tumor suppressor WTX negatively regulates WNT\/\u03b2-catenin signaling. Science. 2007;316:1043\u20136. https:\/\/doi.org\/10.1126\/science\/1141515.","journal-title":"Science"},{"key":"4174_CR165","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1126\/science.1137509","volume":"315","author":"MN Rivera","year":"2007","unstructured":"Rivera MN, Kim WJ, Wells J, et al. An X Chromosome Gene, WTX, Is Commonly Inactivated in Wilms Tumor. Science. 2007;315:642\u20135. https:\/\/doi.org\/10.1126\/science.1137509.","journal-title":"Science"},{"key":"4174_CR166","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3727\/096504017X14992942781895","volume":"25","author":"D Polosukhina","year":"2017","unstructured":"Polosukhina D, Love HD, Moses HL, et al. Pharmacologic inhibition of \u03b2-Catenin with pyrvinium inhibits murine and human models of wilms tumor. Oncol Res. 2017;25:1653\u201364. https:\/\/doi.org\/10.3727\/096504017X14992942781895.","journal-title":"Oncol Res"},{"key":"4174_CR167","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc2676","volume":"9","author":"DB Shackelford","year":"2009","unstructured":"Shackelford DB, Shaw RJ. The LKB1\u2013AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563\u201375. https:\/\/doi.org\/10.1038\/nrc2676.","journal-title":"Nat Rev Cancer"},{"key":"4174_CR168","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-21-1377","author":"J Malhotra","year":"2022","unstructured":"Malhotra J, Ryan B, Patel M, et al. Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer. J Thorac Dis. 2022. https:\/\/doi.org\/10.21037\/jtd-21-1377.","journal-title":"J Thorac Dis"},{"key":"4174_CR169","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","volume":"76","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, et al. STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment. Cancer Res. 2016;76:999\u20131008. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1439.","journal-title":"Cancer Res"},{"key":"4174_CR170","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41698-025-00838-4","volume":"9","author":"G Middleton","year":"2025","unstructured":"Middleton G, Robbins HL, Fletcher P, et al. A phase II trial of mTORC1\/2 inhibition in STK11 deficient non small cell lung cancer. Npj Precis Oncol. 2025;9:67. https:\/\/doi.org\/10.1038\/s41698-025-00838-4.","journal-title":"Npj Precis Oncol"},{"key":"4174_CR171","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12964-024-01689-5","volume":"22","author":"CB Trelford","year":"2024","unstructured":"Trelford CB, Shepherd TG. LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors. Cell Commun Signal. 2024;22:310. https:\/\/doi.org\/10.1186\/s12964-024-01689-5.","journal-title":"Cell Commun Signal"},{"key":"4174_CR172","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.gendis.2014.06.002","volume":"1","author":"W Zhou","year":"2014","unstructured":"Zhou W, Zhang J, Marcus AI. LKB1 tumor suppressor: therapeutic opportunities knock when LKB1 is inactivated. Genes Dis. 2014;1:64\u201374. https:\/\/doi.org\/10.1016\/j.gendis.2014.06.002.","journal-title":"Genes Dis"},{"key":"4174_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113129","volume":"10","author":"E Pons-Tostivint","year":"2021","unstructured":"Pons-Tostivint E, Lugat A, Fontenau J-F, et al. STK11\/LKB1 modulation of the immune response in lung cancer: from biology to therapeutic impact. Cells. 2021;10: 3129. https:\/\/doi.org\/10.3390\/cells10113129.","journal-title":"Cells"},{"key":"4174_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41417-023-00687-y","volume":"31","author":"SM Lenahan","year":"2024","unstructured":"Lenahan SM, Sarausky HM, Deming P, et al. STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines. Cancer Gene Ther. 2024;31:1\u20138. https:\/\/doi.org\/10.1038\/s41417-023-00687-y.","journal-title":"Cancer Gene Ther"},{"key":"4174_CR175","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018;8:822\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0099.","journal-title":"Cancer Discov"},{"key":"4174_CR176","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1128\/MCB.05562-11","volume":"31","author":"Y-H Ahn","year":"2011","unstructured":"Ahn Y-H, Yang Y, Gibbons DL, et al. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor \u03b32 expression. Mol Cell Biol. 2011;31:4270\u201385. https:\/\/doi.org\/10.1128\/MCB.05562-11.","journal-title":"Mol Cell Biol"},{"key":"4174_CR177","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27010100","volume":"27","author":"A Wosiak","year":"2025","unstructured":"Wosiak A, Wodzi\u0144ski D, \u015awiechowski R, et al. Expression and clinical significance of MAPK8, MAPK9, MAP2K4, and MAP2K7 genes in colorectal cancer. Int J Mol Sci. 2025;27: 100. https:\/\/doi.org\/10.3390\/ijms27010100.","journal-title":"Int J Mol Sci"},{"key":"4174_CR178","doi-asserted-by":"publisher","first-page":"8516","DOI":"10.1158\/1078-0432.CCR-04-0885","volume":"10","author":"W Xin","year":"2004","unstructured":"Xin W, Yun KJ, Ricci F, et al. MAP2K4\/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res. 2004;10:8516\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0885.","journal-title":"Clin Cancer Res"},{"key":"4174_CR179","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/ijc.25332","volume":"128","author":"S Yeasmin","year":"2011","unstructured":"Yeasmin S, Nakayama K, Rahman MT, et al. Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition. Int J Cancer. 2011;128:94\u2013104. https:\/\/doi.org\/10.1002\/ijc.25332.","journal-title":"Int J Cancer"},{"key":"4174_CR180","doi-asserted-by":"publisher","unstructured":"Jansen RA, Mainardi S, Dias MH, et al. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers. Proc Natl Acad Sci U S A. n.d.;121:e2319492121. https:\/\/doi.org\/10.1073\/pnas.2319492121.","DOI":"10.1073\/pnas.2319492121"},{"key":"4174_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-173","volume":"11","author":"SJ Davis","year":"2011","unstructured":"Davis SJ, Choong DY, Ramakrishna M, et al. Analysis of the Mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer. BMC Cancer. 2011;11: 173. https:\/\/doi.org\/10.1186\/1471-2407-11-173.","journal-title":"BMC Cancer"},{"key":"4174_CR182","doi-asserted-by":"publisher","first-page":"7495","DOI":"10.3390\/ijms24087495","volume":"24","author":"L Katzengruber","year":"2023","unstructured":"Katzengruber L, Sander P, Laufer S. MKK4 Inhibitors\u2014Recent Development Status and Therapeutic Potential. Int J Mol Sci. 2023;24:7495. https:\/\/doi.org\/10.3390\/ijms24087495.","journal-title":"Int J Mol Sci"},{"key":"4174_CR183","first-page":"2339","volume":"58","author":"GH Su","year":"1998","unstructured":"Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor Gene1. Cancer Res. 1998;58:2339\u201342.","journal-title":"Cancer Res"},{"key":"4174_CR184","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4161\/cbt.5.6.2675","volume":"5","author":"K Nakayama","year":"2006","unstructured":"Nakayama K, Nakayama N, Davidson B, et al. Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther. 2006;5:630\u20134. https:\/\/doi.org\/10.4161\/cbt.5.6.2675.","journal-title":"Cancer Biol Ther"},{"key":"4174_CR185","first-page":"6717","volume":"62","author":"SD Yamada","year":"2002","unstructured":"Yamada SD, Hickson JA, Hrobowski Y, et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma1. Cancer Res. 2002;62:6717\u201323.","journal-title":"Cancer Res"},{"key":"4174_CR186","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102289","volume":"9","author":"JM Pavese","year":"2014","unstructured":"Pavese JM, Ogden IM, Voll EA, et al. Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis. PLoS ONE. 2014;9: e102289. https:\/\/doi.org\/10.1371\/journal.pone.0102289.","journal-title":"PLoS ONE"},{"key":"4174_CR187","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.1038\/sj.onc.1207802","volume":"23","author":"L Wang","year":"2004","unstructured":"Wang L, Pan Y, Dai JL. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene. 2004;23:5978\u201385. https:\/\/doi.org\/10.1038\/sj.onc.1207802.","journal-title":"Oncogene"},{"key":"4174_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-35887-7","volume":"16","author":"A Petniak","year":"2026","unstructured":"Petniak A, Gil-Kulik P, Zarychta J, et al. Reduced expression of BIRC2 and BIRC3 associated with longer survival in pediatric high-grade gliomas. Sci Rep. 2026;16: 6665. https:\/\/doi.org\/10.1038\/s41598-026-35887-7.","journal-title":"Sci Rep"},{"key":"4174_CR189","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433898","volume":"15","author":"Q Meng","year":"2024","unstructured":"Meng Q, Wei K, Shan Y. E3 ubiquitin ligase gene BIRC3 modulates TNF-induced cell death pathways and promotes aberrant proliferation in rheumatoid arthritis fibroblast-like synoviocytes. Front Immunol. 2024;15: 1433898. https:\/\/doi.org\/10.3389\/fimmu.2024.1433898.","journal-title":"Front Immunol"},{"key":"4174_CR190","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3324\/haematol.2019.219550","volume":"105","author":"F Diop","year":"2020","unstructured":"Diop F, Moia R, Favini C, et al. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica. 2020;105:448\u201356. https:\/\/doi.org\/10.3324\/haematol.2019.219550.","journal-title":"Haematologica"},{"key":"4174_CR191","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-020-00521-0","volume":"11","author":"R Frazzi","year":"2021","unstructured":"Frazzi R. BIRC3 and BIRC5: multi\u2010faceted inhibitors in cancer. Cell Biosci. 2021;11: 8. https:\/\/doi.org\/10.1186\/s13578-020-00521-0.","journal-title":"Cell Biosci"},{"key":"4174_CR192","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3324\/haematol.2019.238691","volume":"105","author":"E Tausch","year":"2020","unstructured":"Tausch E, Stilgenbauer S. BIRC3 mutations in chronic lymphocytic leukemia \u2013 uncommon and unfavorable. Haematologica. 2020;105:255\u20136. https:\/\/doi.org\/10.3324\/haematol.2019.238691.","journal-title":"Haematologica"},{"key":"4174_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/srep21710","volume":"6","author":"D Wang","year":"2016","unstructured":"Wang D, Berglund A, Kenchappa RS, et al. BIRC3 is a novel driver of therapeutic resistance in glioblastoma. Sci Rep. 2016;6: 21710. https:\/\/doi.org\/10.1038\/srep21710.","journal-title":"Sci Rep"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04174-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:47:43Z","timestamp":1790005663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04174-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":193,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4174"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04174-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.W.G. and W.W.W. hold equity in Keylicon Biosciences. All other authors have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}